We are live on ! Find out more
VPC

Vestal Point Capital Portfolio holdings

AUM $3.58B
1-Year Est. Return 189.12%
This Fund
S&P 500
This Quarter Est. Return
+12.08%
1 Year Est. Return
+189.12%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.21B
AUM Growth
+$265M
Cap. Flow
+$241M
Cap. Flow %
19.9%
Top 10 Hldgs %
61.52%
Holding
77
New
29
Increased
17
Reduced
10
Closed
19

Top Buys

Rank Stock Value
1
CYTK icon
Cytokinetics
CYTK
+$162M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$52.5M
3
ONC
BeOne Medicines Ltd
ONC
+$52.3M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$45.9M
5
NARI
Inari Medical, Inc. Common Stock
NARI
+$42.7M

Top Sells

Rank Stock Value
1
INBX
Inhibrx, Inc. Common Stock
INBX
+$58.1M
2
MRK icon
Merck
MRK
+$43.6M
3
CBAY
Cymabay Therapeutics
CBAY
+$38.4M
4
PCRX icon
Pacira BioSciences
PCRX
+$34.4M
5
PCVX icon
Vaxcyte
PCVX
+$33M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVAX icon
51
Novavax
NVAX
$1.31B
$2.39M 0.2%
+500,000
New +$2.32M
PCRX icon
52
Pacira BioSciences
PCRX
$997M
$2.34M 0.19%
80,000
-1,120,000
-93% -$34.4M
ATRA icon
53
Atara Biotherapeutics
ATRA
$76.1M
$1.94M 0.16%
+112,000
New +$1.99M
ACHL
54
DELISTED
Achilles Therapeutics
ACHL
$1.88M 0.16%
1,500,000
+1,391,917
+1,288% +$1.5M
CMRX
55
DELISTED
Chimerix, Inc.
CMRX
$1.48M 0.12%
1,400,000
– –
OKUR
56
OnKure Therapeutics
OKUR
$168M
$490K 0.04%
29,538
-10,462
-26% -$173K
AFMD
57
DELISTED
Affimed
AFMD
$292K 0.02%
55,000
+393
+0.7% +$2.24K
LYEL icon
58
Lyell Immunopharma
LYEL
$360M
$290K 0.02%
+6,500
New +$278K
ARQT icon
59
Arcutis Biotherapeutics
ARQT
$3.18B
– –
-2,700,000
Closed -$8.72M
JBIO
60
Jade Biosciences
JBIO
$1.34B
– –
-11,429
Closed -$9.05M
BIIB icon
61
Biogen
BIIB
$30.7B
– –
-75,000
Closed -$19.4M
BLUE
62
DELISTED
bluebird bio
BLUE
– –
-107,500
Closed -$2.97M
CRNX icon
63
Crinetics Pharmaceuticals
CRNX
$8.92B
– –
-450,000
Closed -$16M
EW icon
64
Edwards Lifesciences
EW
$51.7B
– –
-225,000
Closed -$17.2M
IMA
65
ImageneBio Inc
IMA
$64.6M
– –
-26,889
Closed -$636K
MRK icon
66
Merck
MRK
$318B
– –
-400,000
Closed -$43.6M
NUVL
67
DELISTED
Nuvalent
NUVL
– –
-200,000
Closed -$14.7M
OVID icon
68
Ovid Therapeutics
OVID
$491M
– –
-85,429
Closed -$275K
PCVX icon
69
Vaxcyte
PCVX
$8.64B
– –
-525,000
Closed -$33M
PYXS icon
70
Pyxis Oncology
PYXS
$236M
– –
-440,000
Closed -$792K
REGN icon
71
Regeneron Pharmaceuticals
REGN
$80.8B
– –
-10,000
Closed -$8.78M
RVMD icon
72
Revolution Medicines
RVMD
$44B
– –
-725,000
Closed -$20.8M
SNY icon
73
Sanofi
SNY
$104B
– –
-300,000
Closed -$14.9M
TEVA icon
74
Teva Pharmaceuticals
TEVA
$41.2B
– –
-200,000
Closed -$2.09M
VRDN icon
75
Viridian Therapeutics
VRDN
$2.67B
– –
-1,000,000
Closed -$21.8M
1 2
3
4

Similar funds

WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
AAP
Arax Advisory Partners Denver, Colorado $3.54B AUM 19.14% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
TYCC
Texas Yale Capital Corp St. Petersburg, Florida $3.52B AUM 52.63% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return

Vestal Point Capital's Q1 2024 Portfolio in Review

As of Q1 2024, Vestal Point Capital held 77 positions worth $1.21B, up 28% from $944M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Vestal Point Capital deployed $241M of net new capital in Q1 2024, opening 29 new positions and adding to 17 existing holdings. Its largest new stake was BeOne Medicines Ltd: 325,000 shares worth $50.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Pacira BioSciences, an estimated $34.4M trimmed.

  • Vestal Point Capital's largest Q1 2024 buy was BeOne Medicines Ltd: 325,000 shares worth $50.8M.
  • Vestal Point Capital added most to Cytokinetics in Q1 2024, an estimated $162M increase.
  • Vestal Point Capital's biggest Q1 2024 reduction was Pacira BioSciences, cutting an estimated $34.4M.
  • Vestal Point Capital fully exited Inhibrx, Inc. Common Stock in Q1 2024, selling an estimated $58.1M.
  • Vestal Point Capital's ten largest holdings make up 62% of its $1.21B portfolio in Q1 2024.
  • Vestal Point Capital opened 29 new positions and closed 19 in Q1 2024.
  • Vestal Point Capital's portfolio value rose 28% quarter-over-quarter to $1.21B.

Based on Vestal Point Capital's 13F filing for Q1 2024, filed 14 May 2024.